On August 27, JXR (01951) spent approximately HKD 5.9988 million to repurchase 2.627 million shares.
Jinxin Reproductive Medicine (01951) announced that on August 27, 2026, the company plans to spend approximately HKD 5.9988 million to repurchase 2.627 million shares, with a repurchase price ranging from HKD 2.245 to 2.35 per share.
JXR (01951) announced that on August 27, 2026, the company will spend approximately HKD 5.9988 million to repurchase 2.627 million shares, with a repurchase price of HKD 2.245 to 2.35 per share.
Related Articles
China Longyuan Power Group Corporation (00916) released its interim results, with net profit attributable to shareholders of 2.527 billion yuan, a year-on-year decrease of 28.19%.
CGII HLDGS (01940) announced its interim results, with shareholders' profit attributable amounting to 115 million yuan, an increase of 53.57% year-on-year.
I-CABLE COMM (01097) announced its interim results, reporting a loss of HKD 277 million during the period, an increase of 27.53% year-on-year.
China Longyuan Power Group Corporation (00916) released its interim results, with net profit attributable to shareholders of 2.527 billion yuan, a year-on-year decrease of 28.19%.
CGII HLDGS (01940) announced its interim results, with shareholders' profit attributable amounting to 115 million yuan, an increase of 53.57% year-on-year.
I-CABLE COMM (01097) announced its interim results, reporting a loss of HKD 277 million during the period, an increase of 27.53% year-on-year.
RECOMMEND
